Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical cord mesenchymal stem cell transplantation for type 2 diabetes
IRCT20130811014330N10Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Oct 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of allogeneic umbilical cord-derived mesenchymal stem cells in type 2 diabetes mellitus (T2DM), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Effect of UC-MSC injection on disease progression and related symptoms in type 2 diabetes and Inflammatory gene expression. Started Oct 2024; status: completed.
02
Drugs
allogeneic umbilical cord-derived mesenchymal stem cells
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20130811014330N10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130811014330N10.